JAGX מכפיל EV/EBITDA Jaguar Health

Jaguar Health, Inc. (JAGX) specializes in developing plant-based treatments for oncology- and HIV-related diarrhea. This price chart illustrates the impact of Mytesi scaling and the expansion of insurance coverage, with the indicator standing at 0.00. The absence of competitors guarantees the issuer significant pricing power over medication costs. Stable raw material supplies from the Amazon and route optimization completely mitigate the risk of logistical disruptions.

The EV/EBITDA multiple compares the total enterprise value of Jaguar Health, Inc. (JAGX), including net debt, with its operating profit before depreciation and amortization. The current value of 0.00 reflects the company's ability to generate cash flow to service its obligations. Given the absolute non-cyclical nature of demand for Jaguar Health, Inc. (JAGX) maintenance therapy, the company's trend EV/EBITDA level serves as an indicator of the business's fundamental resilience to macroeconomic shocks.